Urogen Pharma (URGN) Expected to Announce Earnings on Wednesday

Urogen Pharma (NASDAQ:URGN) is anticipated to release its Q1 2026 results before the market opens on Wednesday, May 6th. Analysts expect Urogen Pharma to post earnings of ($0.4824) per share and revenue of $44.8280 million for the quarter. Interested persons may review the information on the company’s upcoming Q1 2026 earning report for the latest details on the call scheduled for Wednesday, May 6, 2026 at 10:00 AM ET.

Urogen Pharma (NASDAQ:URGN) last issued its quarterly earnings results on Monday, March 2nd. The company reported ($0.54) EPS for the quarter, beating analysts’ consensus estimates of ($0.66) by $0.12. The business had revenue of $37.84 million for the quarter, compared to the consensus estimate of $39.92 million. On average, analysts expect Urogen Pharma to post $-1 EPS for the current fiscal year and $1 EPS for the next fiscal year.

Urogen Pharma Price Performance

NASDAQ URGN traded up $0.22 on Monday, reaching $23.22. 238,944 shares of the company’s stock traded hands, compared to its average volume of 774,264. Urogen Pharma has a 12 month low of $3.42 and a 12 month high of $30.00. The stock has a 50-day simple moving average of $20.32 and a 200 day simple moving average of $21.39. The stock has a market cap of $1.13 billion, a PE ratio of -7.22 and a beta of 1.58.

Insider Buying and Selling

In other news, General Counsel Jason Drew Smith sold 7,479 shares of the stock in a transaction that occurred on Tuesday, February 3rd. The stock was sold at an average price of $19.69, for a total transaction of $147,261.51. Following the completion of the sale, the general counsel owned 51,326 shares of the company’s stock, valued at approximately $1,010,608.94. This represents a 12.72% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Mark Schoenberg sold 7,373 shares of the stock in a transaction that occurred on Tuesday, February 3rd. The shares were sold at an average price of $19.69, for a total value of $145,174.37. Following the sale, the insider directly owned 144,985 shares of the company’s stock, valued at approximately $2,854,754.65. This trade represents a 4.84% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Corporate insiders own 4.70% of the company’s stock.

Institutional Trading of Urogen Pharma

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Deutsche Bank AG lifted its stake in Urogen Pharma by 126.0% in the fourth quarter. Deutsche Bank AG now owns 366,680 shares of the company’s stock worth $8,588,000 after acquiring an additional 204,421 shares during the period. Parkman Healthcare Partners LLC lifted its stake in Urogen Pharma by 127.8% in the third quarter. Parkman Healthcare Partners LLC now owns 402,595 shares of the company’s stock worth $8,032,000 after acquiring an additional 225,893 shares during the period. Vanguard Group Inc. lifted its stake in Urogen Pharma by 19.1% in the third quarter. Vanguard Group Inc. now owns 303,785 shares of the company’s stock worth $6,061,000 after acquiring an additional 48,814 shares during the period. Informed Momentum Co LLC purchased a new stake in Urogen Pharma in the fourth quarter worth $3,757,000. Finally, TD Asset Management Inc lifted its stake in Urogen Pharma by 82.2% in the fourth quarter. TD Asset Management Inc now owns 80,188 shares of the company’s stock worth $1,878,000 after acquiring an additional 36,188 shares during the period. Hedge funds and other institutional investors own 91.29% of the company’s stock.

Wall Street Analyst Weigh In

A number of analysts have recently weighed in on the company. Oppenheimer reissued an “outperform” rating on shares of Urogen Pharma in a research note on Monday, March 2nd. D. Boral Capital reissued a “buy” rating and set a $33.00 price objective on shares of Urogen Pharma in a research note on Tuesday, March 31st. Weiss Ratings reissued a “sell (d-)” rating on shares of Urogen Pharma in a research note on Monday, April 20th. Finally, Jefferies Financial Group raised Urogen Pharma to a “strong-buy” rating in a research note on Friday, April 24th. One analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $34.13.

About Urogen Pharma

UroGen Pharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for uro-oncology and uro-genital diseases. Founded in 2010 and headquartered in Ra’anana, Israel, with offices in New York, UroGen applies its proprietary RTGel® reverse thermal gel delivery platform to create sustained-release formulations designed for in-office use by urologists.

The company’s lead product, Jelmyto® (mitomycin gel), received U.S. Food and Drug Administration approval in 2020 for the treatment of adults with low-grade upper tract urothelial cancer.